Everything below concerns prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-24. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
On January 10, 2023, Tennessee governor Bill Lee and In-N-Out president Lynsi Snyder announced that a new hub would be built in Franklin, Tennessee, to supply restaurants in the Southeast, beginning in the Nashville area. It is the company's first eastern hub and involved a $125.5 million investment. The first Nashville locations opened in December 2025. On June 9, 2026, In-N-Out opened another location on the Las Vegas strip, located at BLVD. While the location does not have a drive thru, it is In-N-Out's second largest location (behind Barstow, California) at 8,000 square feet. In-N-Out is planning to expand to New Mexico by 2027, with locations in Albuquerque. After expanding to New Mexico, In-N-Out will have a presence in every state in the Southwest.
Milos Vratislav Novotny (born 19 April 1942) is an American chemist, currently the Distinguished Professor Emeritus and Director of the Novotny Glycoscience Laboratory and the Institute for Pheromone Research at Indiana University, and also a published author. Milos Novotny received his Bachelor of Science from the University of Brno, Czechoslovakia in 1962. In 1965, Novotny received his Ph.D. at the University of Brno. Novotny also holds honorary doctorates from Uppsala University, Masaryk University and Charles University, and he has been a major figure in analytical separation methods. Novotny was recognized for the development of PAGE Polyacrylamide Gel-filled Capillaries for Capillary Electrophoresis in 1993. In his years of work dedicated to analytical chemistry he has earned a reputation for being especially innovative in the field and has contributed a great deal to several analytical separation methods. Most notably, Milos has worked a great deal with microcolumn separation techniques of liquid chromatography, supercritical fluid chromatography, and capillary electrophoresis. Additionally, he is known for his research in proteomics and glycoanalysis and for identifying the first mammalian pheromones.
== Diagnosis == The diagnosis of HHV-6 infection is performed by both serologic and direct methods. The most prominent technique is the quantification of viral DNA in blood, other body fluids, and organs by means of real-time PCR.
demethylation The removal of a methyl group (–CH3) from a chemical compound, protein, or other biomolecule, either spontaneously or by enzymatic catalysis. Demethylation is the opposite of methylation; both reactions play important roles in numerous biochemical processes, including in regulating gene expression, as the methylation state of particular residues within particular proteins or nucleic acids can affect their structural conformation in a way that alters their affinity for other molecules, making transcription at nearby genetic loci more or less likely.
Sources: en.wikipedia.org
== Capillary electrochromatography == Capillary electrochromatography (CEC) is an electrochromatography technique in which the liquid mobile phase is driven through a capillary containing the chromatographic stationary phase by electroosmosis. It is a combination of high-performance liquid chromatography and capillary electrophoresis. The capillaries is packed with HPLC stationary phase and a high voltage is applied to achieve separation is achieved by electrophoretic migration of the analyte and differential partitioning in the stationary phase.
== Notable people == Túpac Amaru II, revolutionary Angélica Mendoza de Ascarza, Peruvian human rights activist Kimberly Barzola, American community organizer and artist Benjamin Bratt, American actor Manco Cápac, Sapa Inca Luzmila Carpio, Bolivian musician Andrónico Rodríguez, Bolivian trade unionist and politician Martín Chambi, Peruvian photographer Renata Flores Rivera, Peruvian musician Oswaldo Guayasamín, Ecuadorian painter Ollanta Humala, former president of Peru Antauro Humala, Peruvian ethnocacerist Josh Keaton, American actor Q'orianka Kilcher, American actress Nancy Iza Moreno, Kichwa leader Leonidas Iza, Ecuadorian activist and Indigenous leader Delfín Quishpe, Ecuadorian musician and politician Tarcila Rivera Zea, Peruvian activist Izkia Siches, Chilean physician and politician Magaly Solier, Peruvian actress and musician Diego Quispe Tito, painter Francisco Tito Yupanqui, sculptor Alejandro Toledo, former president of Peru Edison Flores, Peruvian footballer Renato Tapia, Peruvian footballer Tania Pariona Tarqui, Peruvian politician
α‐Hydroxy-β-amino Acid Derivatives Selective low nanomolar inhibitors of IRAP based on the α‐Hydroxy-β-amino scaffold of the drug Ubenimex (Bestatin) have been described, showing excellent selectivity and strong cellular activity in blocking cross presentation.
=== Sleep === Adenosine is a key factor in regulating the body's sleep-wake cycle. Adenosine levels build up in the brain during periods of wakefulness, causing a need to sleep when levels become too high, and lowers during periods of sleep, giving a sensation of restedness when waking. Higher adenosine levels correlate with a stronger feeling of sleepiness, also known as sleep drive or sleep pressure. Cognitive behavioral therapy for insomnia (CBT-I), which is considered one of the most effective treatments for insomnia, utilizes short-term sleep deprivation to raise and regulate adenosine levels in the body, for the intended promotion of consistent and sustained sleep in the long term. A principal component of cannabis delta-9-tetrahydrocannabinol (THC) and the endocannabinoid anandamide (AEA) induces sleep in rats by increasing adenosine levels in the basal forebrain. These components also significantly increase slow-wave sleep during the sleep cycle, mediated by CB1 receptor activation. These findings identify a potential therapeutic use of cannabinoids to induce sleep in conditions where sleep may be severely attenuated.
Males and females are affected equally. The disease was discovered in 1934 by Ivar Asbjørn Følling, with the importance of diet determined in 1935. As of 2023, genetic therapies that aim to directly restore liver PAH activity are a promising and active research field.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.